DYP688

DYP688 is a novel antibody-drug conjugate (ADC) developed for the treatment of metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations. The drug consists of an antibody targeting the protein PMEL17, which is present on GNAQ/11 mutant cancer cells. Upon binding to PMEL17, DYP688 delivers its cytotoxic payload—FR900359, a signaling protein inhibitor—directly to the tumor cell. The payload undergoes unique on-antibody inactivation in plasma but remains active within tumors, resulting in complex pharmacology and potentially improved safety and efficacy profiles. Currently, DYP688 is being evaluated as a single agent in a first-in-human phase I/II clinical trial to determine its safety, tolerability, and anti-tumor activity. Novartis is developing this therapy primarily for patients with metastatic uveal melanoma and other melanomas with GNAQ/11 mutations.